Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Clinical trial NCT04985604 · TERMINATED

Trial details

NCT number: NCT04985604
Sponsor: Day One Biopharmaceuticals, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Solid Tumor CRAF Gene Amplification RAF1 Gene Amplification BRAF Gene Fusion BRAF Fusion CRAF Gene Fusion CRAF Fusion RAF1 Gene Fusion RAF1 Fusion Thyroid Cancer, Papillary Spitzoid Melanoma

Start date: 2021-07-15
Primary completion: 2024-07-08
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.